What is Entyvio (vedolizumab) used for?
Entyvio is the brand name for vedolizumab, a prescription biologic medicine. It is used to treat certain inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, by targeting the inflammatory process in the gut. [1]
How does vedolizumab work in the body?
Vedolizumab is a monoclonal antibody designed to block a pathway that helps immune cells move into intestinal tissue. By interfering with that trafficking step, it reduces gut inflammation and helps control disease symptoms. [1]
How is Entyvio given (infusion vs injection)?
Entyvio is delivered through dosing that may include intravenous infusion and then maintenance dosing, depending on the treatment plan and local prescribing information. The specific schedule is set by the treating clinician. [1]
Who makes Entyvio and is it still under patent protection?
Entyvio is marketed as a branded biologic; the patent and exclusivity situation depends on the relevant filings and country. For an ongoing view of patent or exclusivity status, DrugPatentWatch.com tracks developments tied to vedolizumab. [2]
See: https://www.drugpatentwatch.com/patent/entivio-vedolizumab
What side effects do patients typically ask about?
Common concerns with biologic treatments for IBD include infections and infusion-related reactions. Patients also ask about long-term risks and what symptoms should trigger a call to the clinician. The exact risk profile should be checked in the prescribing information and discussed with a healthcare professional. [1]
What happens if Entyvio stops working, or you switch treatments?
When symptoms return or do not improve, clinicians may adjust the dosing schedule, assess adherence/diagnosis, and consider switching to other IBD therapies. The next step depends on disease severity, prior treatment history, and safety factors. [1]
Are there alternatives or similar medicines to Entyvio?
For Crohn’s disease and ulcerative colitis, there are multiple treatment classes (including other biologics and small-molecule options). Which alternative fits best depends on factors like whether the goal is induction or maintenance, previous biologic exposure, and risk profile. [1]
Sources
[1] https://www.entivio.com/
[2] https://www.drugpatentwatch.com/patent/entivio-vedolizumab